Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna Cetuximab Coverage & Prior Auth Policy Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0684

    Cetuximab (Erbitux)

    Customize your policy alerts

    Sign up for Aetna Policy 0684 alerts

    Get alerted when Policy 0684 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, precertification, and coverage criteria for cetuximab (Erbitux) for commercial medical plans, including approved disease indications, continuation criteria, and investigational uses.

    Policy Summary
    PayerAetna
    PolicyCetuximab (Erbitux)
    Policy CodePolicy 0684
    Change TypeNo material changes
    Effective DateApr 13, 2004
    Last ReviewFeb 2, 2024
    Next Review DateSep 26, 2024
    Key ActionPrecertification is required; submit a Statement of Medical Necessity (SMN) for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J9055HCPCS code for cetuximab (10 mg)
    KRAS/NRAS WTColorectal cancer biomarker requirement
    Continuation permittedReauthorization
    Phase III negativePancreatic cancer trials
    02/02/2024Last review
    04/13/2004Effective date

    Coverage Criteria for Cetuximab (Erbitux)

    Prior Authorization

    Prior Authorization and Documentation

    Prior authorization is required for cetuximab (Erbitux) in accordance with Aetna medical policy procedures. Requests must document the specific indication, prior therapies, and relevant biomarker results when applicable (for example, RAS [KRAS and NRAS], BRAF V600E). Prior authorization is also required for use of cetuximab in off‑label combination regimens; when off‑label combinations are requested, provide supporting clinical evidence or rationale and specify the agents and dosing. Documentation should include prior lines of therapy (chemotherapy, targeted agents, or immunotherapy), dates of progression or intolerance, and the treatment plan for the requested cetuximab regimen.

    • Prior authorization required for all cetuximab requests.
    • Prior authorization required for off‑label combinations; provide clinical justification and supportive evidence.
    • Include biomarker test results (eg, KRAS/NRAS, BRAF V600E) when relevant to the indication.
    Documentation Required

    Biomarker and Genomic Testing Requirements

    Policy Summary
    PayerAetna
    PolicyCetuximab (Erbitux)
    Policy CodePolicy 0684
    Change TypeNo material changes
    Effective DateApr 13, 2004
    Last ReviewFeb 2, 2024
    Next Review DateSep 26, 2024
    Key ActionPrecertification is required; submit a Statement of Medical Necessity (SMN) for prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for Cetuximab (Erbitux)Dosing and Combination RegimensBilling and Coding for CetuximabPrecertification, Prior Authorization & DocumentationBiomarker Testing and Documentation RequirementsIndication by Line of TherapyBackground and Evidence SummaryDefinitions and Key TermsPolicy Dates & Revision History

    Cetuximab use for colorectal cancer is biomarker‑driven: cetuximab is indicated only for RAS (KRAS and NRAS) wild‑type tumors (not for RAS‑mutant or unknown RAS status). For BRAF V600E‑mutant metastatic colorectal cancer, cetuximab is covered only when used in combination with encorafenib. For KRAS G12C‑positive disease, coverage is limited to combinations with the specified KRAS G12C inhibitors and after prior chemotherapy as outlined in the policy. Provide results from FDA‑approved or validated testing methods to confirm mutation status prior to authorization.

    • RAS (KRAS and NRAS) wild‑type confirmation required for routine mCRC cetuximab use.
    • BRAF V600E mutation: cetuximab must be used with encorafenib for covered use.
    • KRAS G12C mutation: covered only in combination with approved G12C inhibitors and after prior chemotherapy.
    Denial Risk

    Off‑Label Combination Requests

    Do not authorize cetuximab when requested for routinely combining with agents listed as experimental/investigational (including panitumumab, erlotinib, gefitinib, bevacizumab, and natural killer cell therapy) outside of clinical trials because safety and effectiveness are not established. The policy notes specific tumor types (eg, pancreatic adenocarcinoma, several listed solid tumors) and combination strategies for which evidence does not support routine coverage—requests for these should be reviewed as investigational and will generally be denied outside a clinical trial.

    • Off‑label combinations with agents listed in the Experimental and Investigational section are not supported and will typically be denied.
    • If an off‑label combination is requested, submit high‑quality supporting evidence (peer‑reviewed clinical trials or guideline support) and rationale; lack of such evidence may result in denial.
    Documentation Required

    Contraindications and Safety Monitoring

    Cetuximab is contraindicated in members with a known hypersensitivity to cetuximab or any component of the formulation. Infusion reactions and cardiopulmonary arrest/sudden death have been reported; infusion should be monitored and cetuximab permanently discontinued for severe infusion reactions. Safety and effectiveness in pediatric and adolescent patients has not been established. Discuss risks with pregnant or breastfeeding patients and document counseling where applicable.

    • Do not initiate cetuximab in patients with known hypersensitivity to cetuximab or components.
    • Closely monitor for infusion reactions; permanently discontinue for serious infusion reactions.
    • Exercise caution in pregnancy or breastfeeding; document counseling.
    • Pediatric/adolescent use not established—prior authorization unlikely without robust supportive data.
    Denial Risk

    Avoid Combinations with Excessive Mortality Risk

    Avoid regimens or combinations associated with excessive treatment‑related mortality. The policy cites trials in advanced NSCLC where combinations (eg, carboplatin/paclitaxel plus cetuximab and certain investigational antibodies) had excessive grade 5 adverse events and were closed early; such combinations should not be authorized outside controlled trials.

    • Do not authorize combinations shown to have excessive grade 5 AEs in clinical trials (provide trial citation if used in justification).
    • If prior treatment led to significant toxicity or early deaths in trial data, require strong justification and safety monitoring plan for any similar proposed regimen.
    Denial Risk

    Pancreatic Adenocarcinoma

    Routine use of cetuximab in unselected pancreatic adenocarcinoma is not supported by high‑quality evidence (phase III trials and meta‑analyses show no survival or PFS benefit and increased toxicity). Requests for cetuximab in pancreatic adenocarcinoma will generally be denied unless part of a well‑designed clinical trial with a strong scientific rationale.

    • Phase III evidence (eg, cetuximab + gemcitabine) demonstrated no clinically significant benefit; routine coverage is not provided.
    • For pancreatic cancer, authorize only within clinical trial protocols with appropriate oversight and justification.
    Step Therapy

    Exhaustion of Standard Therapy and Step Therapy Considerations

    The policy requires that standard, guideline‑recommended therapies be exhausted or documented as inappropriate or not tolerated before considering cetuximab for many indications (for example, prior chemotherapy for KRAS G12C‑positive colorectal cancer combinations). Where the policy specifies prior lines (eg, progression on EGFR tyrosine kinase inhibitor therapy in NSCLC before EGFR inhibitor combinations), include prior therapy details in the authorization request. The policy does not specify step‑therapy prior authorizations beyond these clinical sequencing requirements.

    • Document prior standard therapies and reasons for discontinuation (progression, intolerance, contraindication).
    • No separate step‑therapy authorization program is specified in this section beyond clinical sequencing requirements.
    • If policy requires prior exposure to a specified agent (eg, prior EGFR TKI in NSCLC), include dates and outcomes of that therapy.
    Note

    Administrative / Informational Notes

    Some portions of this section are informational or administrative (eg, Experimental and Investigational lists, background summaries) and do not themselves establish coverage beyond the policy criteria. Administrative notes or general background do not replace the requirement for prior authorization and documentation of medical necessity.

    • Background material and literature summaries are informational only and do not constitute authorization.
    • Follow policy coverage criteria and prior authorization rules when making coverage determinations.

    Dosing and Combination Regimens

    RegimenDosing / ScheduleIndicationCoverage status
    Cetuximab (single-agent or in combination with irinotecan or FOLFIRI)
    Weekly: 400 mg/m2 IV loading dose (120-minute infusion) then 250 mg/m2 IV every week (60-minute infusion); Biweekly: 500 mg/m2 IV every 2 weeks (120-minute infusion). Administer 1 hour prior to irinotecan or FOLFIRI.
    Metastatic colorectal cancer — single agent or combined with irinotecan/FOLFIRI per indication
    covered with criteria (see policy for biomarker and line-of-therapy requirements)
    RegimenDosing / ScheduleIndication / SettingCoverage status
    Cetuximab + FOLFIRI
    Cetuximab dosing per schedule: initial 400 mg/m2 IV then 250 mg/m2 weekly (or 500 mg/m2 biweekly); administer 1 hour prior to FOLFIRI
    First-line metastatic colorectal cancer in appropriate patients (see KRAS/NRAS/BRAF biomarker requirements)
    covered with criteria
    RegimenEvidence summaryImplicationCoverage status
    Bevacizumab combined with cetuximab or panitumumab
    Meta-analysis of randomized trials (4 RCTs, 2,069 patients) found no significant improvement in PFS or OS and no increase in ORR with the addition of bevacizumab to cetuximab/panitumumab-based therapy (Lv et al, 2015)
    Combination not recommended due to lack of demonstrated benefit
    not_covered
    RegimenStudy phase / dosingResults / notesCoverage status
    GEMOX (gemcitabine + oxaliplatin) + cetuximab
    Cetuximab 400 mg/m2 loading then 250 mg/m2 weekly with gemcitabine 1000 mg/m2 day 1 and oxaliplatin 100 mg/m2 day 2 every 2 weeks (per phase II trial)
    Phase II in advanced hepatocellular carcinoma: confirmed response rate ~20%, disease stabilization in 40%; randomized trial planned
    experimental
    RegimenDosing / scheduleStudy findingsCoverage status
    Cetuximab + gemcitabine/platinum
    Cetuximab dosing per standard schedule (400 mg/m2 loading then 250 mg/m2 weekly or 500 mg/m2 biweekly) administered with gemcitabine and platinum per trial protocols
    Randomized phase II (Butts et al) showed partial responses and acceptable toxicity; mixed results across trials with modest or inconsistent benefit
    experimental
    RegimenDosing / scheduleStudy observationsCoverage status
    Cetuximab + bevacizumab + irinotecan
    Cetuximab 400 mg/m2 loading then 250 mg/m2 weekly given with bevacizumab (5–10 mg/kg q2wk) and irinotecan (dose per protocol)
    Phase II in recurrent GBM reported radiographic responses (34% radiographic response among evaluable patients) but did not demonstrate superiority over bevacizumab/irinotecan alone
    experimental
    RegimenDosing / scheduleEvidence / safety notesCoverage status
    Cetuximab + cisplatin/vinorelbine; Cetuximab + carboplatin/paclitaxel; Cetuximab + gemcitabine/cisplatin
    Cetuximab per standard dosing combined with listed platinum regimens as used in cited trials
    Phase II and randomized phase II trials reported mixed efficacy; some trials suggested modest activity while others showed no clear benefit and, in some combinations, safety concerns or increased toxicity
    investigational
    RegimenDosing / scheduleIndicationCoverage status
    Weekly cetuximab dosing regimen (loading then weekly maintenance)
    Initial dose: 400 mg/m2 IV (120-minute infusion) as loading dose; subsequent weekly doses: 250 mg/m2 IV (60-minute infusion)
    Used for unresectable cutaneous squamous cell carcinoma (cetuximab monotherapy trials) and as standard weekly schedule for SCCHN when given with radiation or chemotherapy
    covered with criteria (see policy for specific indications)
    Example regimenDosing / schedule (cetuximab component)Setting / trial phaseCoverage status
    Encorafenib + cetuximab (± alpelisib)
    Cetuximab administered per standard (400 mg/m2 loading then 250 mg/m2 weekly); encorafenib and alpelisib dosed per phase Ib protocol (eg, encorafenib 200 mg)
    Phase Ib dose-escalation in BRAF-mutant mCRC showed confirmed ORR ~18–19% and median PFS ~3.7–4.2 months; tolerable safety profile
    experimental

    Billing and Coding for Cetuximab

    CPT codes covered if selection criteria are metCPTCovered
    81275KRAS gene analysis; variants in exon 2 (eg, codons 12 and 13).
    81276Additional variant(s) (eg, codon 61, codon 146).
    88363Examination and selection of retrieved archival tissue(s) for molecular analysis (eg, KRAS mutational analysis).
    96401-96450Chemotherapy administration.
    HCPCS codes covered or relatedHCPCSCovered
    J9055Injection, cetuximab, 10 mg.
    J9206Injection, irinotecan, 20 mg.
    J9190Injection, fluorouracil, 500 mg.
    J9263Injection, oxaliplatin, 0.5 mg.
    J9303Injection, panitumumab, 10 mg.
    J9035Injection, bevacizumab, 10 mg.
    J8565Gefitinib, oral, 250 mg.
    J0640Injection, leucovorin calcium, per 50 mg.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    C18.0-C21.8Malignant neoplasm of colon, rectosigmoid junction, rectum, anus and anal canal (covered for colorectal indications as specified).
    C00.0-C08.1, C09.0-C14.8Malignant neoplasm of lip, oral cavity, and pharynx (covered for squamous cell carcinoma of the head and neck only).
    C34.00-C34.92Malignant neoplasm of bronchus and lung (non-small cell lung cancer).
    C44.xx (multiple)Squamous cell carcinoma of skin (various sites).
    C60.0-C60.9Malignant neoplasm of penis.
    ICD-10 codes not covered for indications listedICD-10Not Covered
    C15.3-C15.9Malignant neoplasm of esophagus (esophageal adenocarcinoma) - not covered.
    C16.0-C16.9Malignant neoplasm of stomach (gastric cancer) - not covered.
    C22.0-C22.4Liver cell carcinoma and related hepatic neoplasms - not covered.
    C25.0-C25.9Malignant neoplasm of pancreas - not covered.
    C50.011-C50.929Malignant neoplasm of breast - not covered.
    C61Malignant neoplasm of prostate - not covered.
    Dosage summary — Erbitux (cetuximab)
    Loading doseInitial 400 mg/m2 IV (120-minute infusion)
    Weekly maintenance250 mg/m2 IV every week (60-minute infusion)
    Biweekly maintenance500 mg/m2 IV every 2 weeks (120-minute infusion)
    Administration timingAdminister cetuximab 1 hour prior to concurrent irinotecan, FOLFIRI, platinum-based therapy, or radiation as specified by indication

    Precertification, Prior Authorization & Documentation

    Prior Authorization

    Precertification required

    Precertification (preauthorization) of cetuximab (Erbitux) is required for Aetna participating providers and members in applicable plan designs; providers should call or fax the numbers listed and submit a Statement of Medical Necessity (SMN) as indicated.

    • Call (866) 752-7021 or fax (888) 267-3277 for precertification.
    • SMN precertification forms available via Aetna Specialty Pharmacy Precertification resources.
    Prior Authorization

    Prior authorization: confirm indication, prior therapies, and progression

    Prior authorization reviews must confirm the requested indication and prior therapies/progression consistent with the policy (for example, metastatic colorectal cancer, head and neck cancer, prior irinotecan exposure where applicable, and tumor KRAS/RAS status).

    • For mCRC, prior authorization should document prior irinotecan exposure and progression status consistent with pivotal trial populations.
    • For biomarker‑driven indications, confirm KRAS/NRAS (RAS) wild‑type status or other specified mutation-based pathways.
    Prior Authorization

    Prior authorization for off‑label combinations: document line of therapy and evidence

    When cetuximab is requested in combination regimens that are off‑label or have limited trial evidence, prior authorization must include documentation of line of therapy and supporting clinical evidence from trials or publications.

    • Examples include GEMOX + cetuximab in HCC and cetuximab plus platinum/gemcitabine regimens in NSCLC where phase II evidence is limited.
    • Specify whether the request is for first‑line, second‑line, or refractory setting and cite supporting study data.
    Prior Authorization

    Prior authorization for off‑label indications: include rationale, prior therapies, and evidence

    For off‑label indications, prior authorization requests must include the clinical rationale, prior therapies tried, and supporting evidence (clinical trial data, case series, or biomarker data) to justify use outside approved indications.

    • Examples of off‑label uses requiring justification include NSCLC, penile cancer, salivary duct carcinoma, and cutaneous SCC in selected settings.
    • Provide trial citations or biomarker results (EGFR IHC/FISH, KRAS status) when available to support potential benefit.
    Prior Authorization

    Prior authorization for combination regimens: include trial phase, dosing, and safety data

    When requesting cetuximab for combination regimens outside standard indications, prior authorization should include trial phase, dosing schema, and safety/efficacy data from the supporting studies.

    • Include phase I/II trial details such as recommended phase II dose, dose‑limiting toxicities (DLTs), and observed response rates (e.g., pazopanib 800 mg/day + cetuximab schedule).
    • Document how the requested dosing matches the published regimen and any modifications with supporting justification.
    Note

    Prior authorization — no additional PA codes specified here

    This section of the document does not specify additional prior authorization codes or unique administrative prior authorization procedures beyond the general precertification requirement.

    Note

    Prior authorization — not specified in additional information

    No additional prior authorization requirements are specified in the supplemental/administrative portion of this policy.

    Documentation Required

    Biomarker prerequisite: document KRAS/NRAS wild‑type (or specified mutation pathway) for CRC

    For colorectal cancer indications, prior documentation of KRAS and NRAS (RAS) wild‑type status (or the specific biomarker-driven mutation pathway requested) is required to establish eligibility per policy.

    • Policy requires RAS (KRAS and NRAS) mutation status negative (wild‑type) for standard CRC pathway.
    • If BRAF V600E positive, indicate planned combination with encorafenib; if KRAS G12C positive, indicate combination with sotorasib or adagrasib and prior chemotherapy.
    Step Therapy

    Step therapy consideration: document prior standard therapies (irinotecan, platinum chemoradiation)

    Prior standard therapies should be documented and considered before cetuximab (for example, prior irinotecan‑based regimens in mCRC and platinum‑based chemoradiation in head & neck cancer).

    • For mCRC, document prior irinotecan exposure/progression where applicable.
    • For HNSCC, document intolerance or contraindication to platinum‑based chemoradiation if substituting cetuximab with radiation.
    Step Therapy

    Exhaust standard therapy first: document prior established standard treatments

    Providers must document that established standard therapies were attempted or are unsuitable before initiating cetuximab in non‑standard settings (e.g., RT with 5‑FU and mitomycin is standard for anal cancer).

    • State why standard-of-care options are not appropriate or have failed prior to cetuximab use.
    • Cite prior treatment dates, regimens, and response/progression details.
    Prior Authorization

    Step therapy / substitution with cisplatin: document why cisplatin is ineligible

    When cetuximab is proposed as an alternative to cisplatin‑based concurrent therapy (e.g., with radiotherapy in HNSCC), the prior authorization should state the clinical rationale and document why cisplatin is ineligible.

    • Note that meta‑analysis shows inferior outcomes with cetuximab+RT versus cisplatin+RT; document contraindications to cisplatin (e.g., comorbidities) if substitution is requested.
    • Include supporting clinical evidence or comorbidity details in the request.
    Documentation Required

    Position after standard therapy: document refractory status and prior lines

    Evidence evaluated cetuximab in refractory patients after prior lines of therapy in several tumor types; prior authorization should document prior lines and refractory status when requesting cetuximab in later‑line settings.

    • Examples include BRAF‑mutant mCRC after prior therapies and metastatic gastric cancer second‑line combinations.
    • Provide prior line counts, dates, and responses to prior regimens.
    Documentation Required

    Precertification and SMN: submit Statement of Medical Necessity

    Providers should submit a Statement of Medical Necessity (SMN) as part of the precertification process for cetuximab requests.

    • SMN forms available via Aetna Specialty Pharmacy Precertification resources.
    • Precertification contact: call (866) 752-7021 or fax (888) 267-3277.
    Documentation Required

    Required clinical documentation: prior irinotecan exposure and progression for mCRC

    For metastatic colorectal cancer requests, include documentation of prior irinotecan exposure and progression status consistent with pivotal trial populations when applicable.

    • Cite trial population details if relying on evidence from irinotecan‑refractory studies (e.g., response rates and time to progression).
    • Include dates and regimens for prior chemotherapy and evidence of progression.
    Documentation Required

    Evidence rationale for off‑label use: document prior therapies, severity, and rationale

    When seeking cetuximab for rare or off‑label conditions, include documentation of prior therapies tried, clinical severity, and a clear rationale with supporting evidence to justify non‑approved use.

    • Provide case series or trial references if available (e.g., Menetrier's disease reports).
    • Describe functional impairment, prior interventions, and why cetuximab is expected to benefit.
    Documentation Required

    Biomarker documentation: include EGFR IHC/FISH and KRAS results

    Include biomarker test results (EGFR IHC, EGFR FISH, KRAS status) and prior molecular testing or trial enrollment details when submitting for authorization in biomarker‑selected or investigational scenarios.

    • EGFR IHC positivity or EGFR FISH high gene copy number have been used in trials and may be relevant to support off‑label consideration.
    • Provide lab reports with test method, date, and result (e.g., EGFR FISH score 5–6 = high FISH).
    Documentation Required

    Document dose escalation and DLTs for combination regimens

    For requests involving combination regimens derived from early‑phase trials, document dose‑escalation details, dose‑limiting toxicities (DLTs), and the recommended phase II dose as reported in the supporting study.

    • Provide the published dosing schema (e.g., pazopanib 800 mg/day + cetuximab loading 400 mg/m2 then 250 mg/m2 weekly).
    • Document observed DLTs and how planned dosing mitigates those risks.
    Note

    Administrative note: no extra documentation listed here

    This administrative portion of the policy does not list additional required documentation for prior authorization; refer to the main policy sections for clinical documentation requirements.

    Note

    Administrative supplemental: no documentation requirements in this section

    Administrative and legal notices in the Additional Information section do not specify clinical documentation requirements for prior authorization.

    Note
    Denial Risk

    Contraindications/high‑risk use: hypersensitivity, pediatric, pregnancy/breastfeeding

    Requests for cetuximab that involve hypersensitivity to cetuximab, use in pediatric/adolescent patients, or in pregnant/breastfeeding members without documented risk/benefit discussion are at risk for denial.

    • Erbitux should not be used in members with hypersensitivity to cetuximab or any component.
    • Safety/effectiveness in pediatric/adolescent patients is not established; pregnancy/breastfeeding requires documented risk/benefit discussion.
    Denial Risk

    Denial risk: excessive treatment‑related mortality in prior trials

    Trials reporting excessive treatment‑related mortality or lack of efficacy (for example, the Hanna et al. NSCLC trial closed early for excessive grade 5 AEs) support denial for similar high‑risk combinations without demonstrated benefit.

    • Hanna et al (2015) trial closed early due to an excessive number of grade 5 adverse events and lacked efficacy signal for certain combinations.
    • Provide safety data and rationale if requesting coverage for regimens with similar safety concerns.
    Denial Risk

    Denial risk: pancreatic adenocarcinoma — lack of efficacy

    Requests for cetuximab to treat pancreatic adenocarcinoma in unselected patients risk denial because randomized phase III trials and a meta‑analysis showed no survival or PFS benefit and similar or increased toxicity.

    • Philip et al (2007) phase III trial (n=735) showed no significant OS or PFS benefit adding cetuximab to gemcitabine.
    • Systematic review/meta‑analysis (Forster et al 2020) of 4 RCTs (924 patients) found no OS/PFS/objective response benefit and similar or increased toxicity.
    Denial Risk

    Denial risk: urothelial carcinoma combinations showed increased toxicity/no outcome benefit

    Addition of cetuximab to gemcitabine/cisplatin in urothelial carcinoma increased adverse events without improving outcomes; requests for this combination in unselected UC patients may be denied.

    • Randomized phase II trial (Hussain et al. 2014) showed similar ORR, no PFS/OS benefit, and more grade 3/4 AEs (and some grade 5 events) with GC + cetuximab.
    • Provide biomarker‑selected evidence if arguing for coverage in specific UC subgroups.

    Biomarker Testing and Documentation Requirements

    KRAS/NRAS (RAS) — wild-type requirement
    DefinitionRAS (KRAS and NRAS) wild-type = absence of activating mutations in KRAS and NRAS genes
    Clinical relevanceRequired biomarker for cetuximab efficacy in metastatic colorectal cancer per policy; requests in RAS-mutant disease are not indicated
    Testing recommendationKRAS testing is recommended prior to initiating cetuximab or panitumumab therapy to predict benefit
    BRAF V600E — mutation-positive
    MarkerBRAF V600E mutation-positive
    ImplicationIf BRAF V600E positive in metastatic CRC, cetuximab should be used in combination with encorafenib
    EvidenceFDA indication: combination with encorafenib for BRAF V600E-mutant metastatic colorectal cancer after prior therapy
    KRAS G12C — G12C mutation-positive
    MarkerKRAS G12C mutation-positive
    ImplicationWhen G12C positive in colorectal cancer, policy specifies use in combination with sotorasib or adagrasib after prior chemotherapy
    Line of therapyCombination pathway requires prior chemotherapy exposure per policy
    EGFR sensitizing mutations — examples
    Examples of sensitizing EGFR mutationsExon 19 deletion, L858R, S768I, L861Q, G719X
    ContextRequired for NSCLC subsequent therapy eligibility when cetuximab is used after progression on EGFR TKIs in combination with afatinib
    Source trialsListed as examples of known sensitizing mutations in policy eligibility criteria
    KRAS — wild-type as predictive biomarker
    KRAS statusKRAS wild-type = absence of activating KRAS mutation
    Predictive roleKRAS wild-type is a predictive biomarker for likely benefit from EGFR inhibitors such as cetuximab in colorectal cancer
    Trial analysesRetrospective and subgroup analyses in trials support KRAS wild-type association with benefit
    EGFR amplification/mutation, KRAS — inconsistent correlation
    Study findingsStudies reported EGFR amplification/mutation and KRAS testing but found no consistent reliable correlation with response to cetuximab in gliomas and BAC trials
    InterpretationEGFR amplification did not consistently predict benefit; few responders were identified regardless of amplification status
    ImplicationNo specific quantitative threshold for EGFR or KRAS established as predictive in these tumor types
    EGFR testing methods (IHC, FISH, gene copy number)
    Testing methodsEGFR IHC, EGFR FISH, and gene copy number analyses were used in trials
    Notable resultIn SWOG 0342, patients with high EGFR FISH (score 5–6) had longer median PFS (~6 months) versus low FISH (scores 1–4) with median PFS ~3 months
    Trial enrollmentEGFR IHC positivity was required for enrollment in some trials (eg, FLEX), demonstrating varied use of assays
    KRAS — subgroup suggested for pancreatic cancer research
    Suggested subgroupKRAS wild‑type identified as a possible subgroup for further research in pancreatic cancer
    RationalePhase III and meta-analyses showed no overall benefit of cetuximab in unselected pancreatic cancer; small KRAS WT subset may warrant study
    RecommendationFurther research should examine benefit of cetuximab in KRAS wild‑type pancreatic tumors rather than routine use
    Other biomarkers (BRAF, PIK3CA, VEGF)
    Other biomarkers referencedBRAF, PIK3CA, VEGF mentioned in exploratory analyses or as potential predictors
    Clinical contextBRAF mutation was the target for encorafenib+cetuximab combinations; PIK3CA and VEGF were explored as potential predictors in small subgroups
    ThresholdsNo detailed quantitative thresholds for these biomarkers are provided in the policy excerpts
    Documentation Required

    Biomarker documentation required: include EGFR IHC, EGFR FISH, KRAS and molecular testing reports

    When submitting for authorization, include EGFR IHC, EGFR FISH, KRAS status, and molecular testing results when relevant to support biomarker‑driven or investigational requests.

    • EGFR FISH high (score 5–6) associated with longer PFS in one NSCLC trial (SWOG 0342).
    • Include specific assay results, dates, and interpretation in the submission.

    Indication by Line of Therapy

    first-line

    first-line: Use as first-line where specified (for example cetuximab + FOLFIRI in KRAS/NRAS wild‑type metastatic colorectal cancer per FDA indication).

    Line of therapy determined by indication and trial evidence

    subsequent

    subsequent: Use in subsequent‑line settings where specified (for example single‑agent cetuximab for metastatic penile cancer or NSCLC after EGFR TKI progression when combined with afatinib).

    Requires prior therapy per indication

    first-line and second-line

    first-line and second-line: Situations where cetuximab has been evaluated in both first‑line and second‑line contexts (eg, metastatic colorectal cancer: first‑line with FOLFIRI; second‑line after irinotecan).

    Refer to indication‑specific criteria

    first-line | second-line

    first-line | second-line: Contexts in NSCLC and other tumors where cetuximab has been studied in either first‑line combinations with chemotherapy or as second‑line/salvage monotherapy depending on study design.

    Line varies by published trial

    first-line | salvage

    first-line | salvage: Settings where cetuximab was evaluated as first‑line in combination regimens or as salvage therapy (eg, NSCLC first‑line combos; cutaneous SCC first‑line monotherapy; various tumors in salvage settings).

    Evidence mixed across studies

    second-line

    second-line: Use as second‑line or later in refractory populations has been evaluated in several tumor types (eg, BRAF‑mutant mCRC after prior lines; mFOLFIRI + cetuximab in gastric cancer second‑line).

    Often after exhaustion of standard therapies

    Background and Evidence Summary

    Cetuximab dosing follows the prescribed regimens: an initial loading dose of 400 mg/m2 IV followed by 250 mg/m2 weekly or 500 mg/m2 biweekly as specified by indication and regimen. Specific administration schedules depend on the tumor type and combination regimen.

    inv-10 (supporting context): Head & neck evidence comparison and trial outcomes summarized

    Head & neck evidence comparison: Meta‑analysis and retrospective data indicate inferior outcomes for cetuximab+RT versus cisplatin+RT; cetuximab should be used with caution and only when cisplatin is contraindicated, documenting the reason.

    Li et al (2023) and retrospective series summarized

    Evidence summaries for pancreatic adenocarcinoma demonstrate lack of efficacy: a large phase III trial of gemcitabine plus cetuximab failed to show survival or PFS benefit, and a meta‑analysis of randomized trials found no OS/PFS/objective response advantage and similar or higher toxicity. These high‑quality randomized data support excluding routine cetuximab use in unselected pancreatic cancer patients.

    Definitions and Key Terms

    Erbitux (cetuximab) — definition and mechanism
    Drug class and targetErbitux (cetuximab) is a recombinant chimeric (human/mouse) monoclonal antibody that binds the epidermal growth factor receptor (EGFR)
    Mechanism of actionBinds EGFR and inhibits downstream signaling involved in tumor growth, survival, proliferation, and motility
    Indications summaryUsed in colorectal cancer and squamous cell carcinoma of the head and neck; approved combinations include FOLFIRI and encorafenib for BRAF V600E
    RAS (KRAS/NRAS) wild-type — definition
    DefinitionRAS (KRAS/NRAS) wild-type = absence of activating mutations in KRAS and NRAS genes
    Policy implicationRequired to determine eligibility for cetuximab in metastatic colorectal cancer; Ras-mutant CRC is not indicated for cetuximab
    Testing guidanceClinical guidance and trials recommend KRAS testing prior to EGFR inhibitor therapy
    EGFR — definition and role
    DefinitionEGFR (epidermal growth factor receptor) is a transmembrane receptor tyrosine kinase involved in cell proliferation and survival
    Role in tumorsEGFR is overexpressed in many epithelial cancers (eg, colorectal, head and neck) and contributes to tumor progression and resistance
    Therapeutic targetEGFR inhibitors (monoclonal antibodies and TKIs) interrupt signaling and can impair tumor cell proliferation
    KRAS wild-type — predictive biomarker
    KRAS wild-type definitionAbsence of activating KRAS mutations
    Predictive usePredictive biomarker for benefit from EGFR inhibitors such as cetuximab in metastatic colorectal cancer
    Policy noteErbitux is indicated for K-Ras wild-type, EGFR-expressing colorectal cancer; not indicated for Ras-mutant tumors
    EGFR and EGFRvIII — definitions
    EGFR definitionEGFR is a cell-surface receptor tyrosine kinase implicated in tumor proliferation and survival
    EGFRvIIIEGFRvIII is a constitutively active mutant variant seen in some glioblastomas and may contribute to aggressive behavior
    Clinical implicationEGFR and EGFRvIII are investigational targets in CNS tumors; clinical benefit of EGFR-targeted agents remains unproven in many CNS settings
    EGFR FISH high vs low — scoring note
    Scoring noteEGFR FISH scoring in SWOG 0342: scores 1–4 = low FISH; scores 5–6 = high FISH
    Associated outcomeHigh FISH (scores 5–6) associated with longer median PFS (~6 months) versus low FISH (~3 months) in that trial
    ImplicationEGFR FISH positivity may have predictive value in select NSCLC analyses but is not uniformly validated
    EGFR IHC — definition and trial use
    DefinitionEGFR IHC = immunohistochemical detection of EGFR protein expression in tumor tissue
    Trial useEGFR IHC positivity was required for enrollment in some trials (eg, FLEX) and has been explored as a predictive biomarker with mixed results
    Clinical observationEGFR IHC-negative patients had worse survival in some single-arm NSCLC studies compared to IHC-positive patients
    DLT/MTD — definitions
    DLT definitionDose-limiting toxicity (DLT) = treatment-related toxicity used to define tolerable dose limits in early-phase trials
    MTD definitionMaximum tolerated dose (MTD) = highest dose level at which predefined DLTs are acceptable during escalation studies
    RelevanceDLTs and MTDs were reported in phase I/Ib studies of cetuximab combinations to identify safe dosing and recommended phase II doses

    Policy Dates & Revision History

    This supplemental administrative section provides links to the policy's history and definitions and includes Aetna's legal and contact information. It does not itself change coverage criteria or list clinical exclusions.

    This supplemental portion does not specify prior authorization procedures. The policy history panel documents the last review date 02/02/2024, the effective date 04/13/2004, and the next review date 09/26/2024, but explicit prior authorization codes or processes are provided elsewhere in the main policy text.